Exogenous hCG activity, but not endogenous LH activity, is positively associated with live birth rates in anovulatory infertility
- PMID: 21732905
- PMCID: PMC3251000
- DOI: 10.3109/14647273.2011.587135
Exogenous hCG activity, but not endogenous LH activity, is positively associated with live birth rates in anovulatory infertility
Abstract
Objective: To evaluate, retrospectively, the roles of endogenous and exogenous luteinising hormone (LH) activity on live birth rate in ovulation induction cycles.
Methods: Associations between LH activity at baseline, end of stimulation and live birth rate were analysed in relation to patient characteristics, baseline and end of stimulation variables in WHO group II anovulatory women (n = 155) stimulated with recombinant follicle-stimulating hormone (rFSH) or highly purified human menopausal gonadotrophin (HP-hMG). HP-hMG provides FSH and exogenous LH activity mainly in the form of human chorionic gonadotrophin (hCG).
Results: Serum LH concentrations at baseline or end of stimulation were not predictive of live birth rate in the rFSH group (n = 79) or HP-hMG group (n = 76). Serum hCG concentration at end of stimulation was a significant positive predictor in HP-hMG-treated women. Other variables were not independently predictive of live birth in either of the groups, except for a negative association between serum FSH concentrations at the start of stimulation and live birth in the rFSH-treated group.
Conclusions: Endogenous LH concentrations are not predictive of live birth in anovulatory WHO group II patients undergoing ovulation induction with rFSH or HP-hMG. On the other hand, exogenous hCG activity during HP-hMG stimulation is positively associated with treatment outcome.
Figures
Similar articles
-
Live-birth rates after HP-hMG stimulation in the long GnRH agonist protocol: association with mid-follicular hCG and progesterone concentrations, but not with LH concentrations.Gynecol Endocrinol. 2013 Jan;29(1):46-50. doi: 10.3109/09513590.2012.705379. Epub 2012 Jul 19. Gynecol Endocrinol. 2013. PMID: 22809021 Free PMC article.
-
Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study.Hum Reprod. 2006 Jul;21(7):1798-804. doi: 10.1093/humrep/del085. Epub 2006 Mar 29. Hum Reprod. 2006. PMID: 16571641 Clinical Trial.
-
Highly purified hMG versus recombinant FSH plus recombinant LH in intrauterine insemination cycles in women ≥35 years: a RCT.Hum Reprod. 2015 Jan;30(1):179-85. doi: 10.1093/humrep/deu302. Epub 2014 Nov 14. Hum Reprod. 2015. PMID: 25398971 Clinical Trial.
-
Identifying real differences in live birth rates between HMG and rFSH in IVF.Reprod Biomed Online. 2009;18 Suppl 2:25-30. doi: 10.1016/s1472-6483(10)60445-2. Reprod Biomed Online. 2009. PMID: 19406028 Review.
-
Benefits of luteinizing hormone activity in ovarian stimulation for IVF.Reprod Biomed Online. 2009;18 Suppl 2:31-6. doi: 10.1016/s1472-6483(10)60446-4. Reprod Biomed Online. 2009. PMID: 19406029 Review.
Cited by
-
Influence of human chorionic gonadotrophin during ovarian stimulation: an overview.Reprod Biol Endocrinol. 2020 Aug 6;18(1):80. doi: 10.1186/s12958-020-00639-3. Reprod Biol Endocrinol. 2020. PMID: 32762698 Free PMC article. Review.
-
Live-birth rates after HP-hMG stimulation in the long GnRH agonist protocol: association with mid-follicular hCG and progesterone concentrations, but not with LH concentrations.Gynecol Endocrinol. 2013 Jan;29(1):46-50. doi: 10.3109/09513590.2012.705379. Epub 2012 Jul 19. Gynecol Endocrinol. 2013. PMID: 22809021 Free PMC article.
References
-
- Acevedo B., Sanchez M., Gomez J. L., Cuadros J., Ricciarelli E., Hernández E. R. Luteinizing hormone supplementation increases pregnancy rates in gonadotropin-releasing hormone antagonist donor cycles. Fertility & Sterility. 2004;82:343–347. - PubMed
-
- Balasch J. In: The role of FSH and LH in ovulation induction: current concepts and the contribution of recombinant gonadotropins. Textbook of assisted reproductive techniques: laboratory and clinical perspectives. 2nd. Gardner D. K., Weissman A., Howies C. M., Shoham Z., editors. edLondonTaylor and Francis; 2004. pp. 541–565.
-
- Balasch J., Fábregues F, Casamitjana R., Penarrubia J., Vanrell J. A. A pharmacokinetic and endocrine comparison of recombinant follicle-stimulating hormone and human menopausal gonadotrophin in polycystic ovary syndrome. Reproductive Biomedicine Online. 2003;6:296–301. - PubMed
-
- Balen A. H., Braat D.D., West C., Patel A., Jacobs H.S. Cumulative conception and live birth rates after the treatment of anovulatory infertility: safety and efficacy of ovulation induction in 200 patients. Human Reproduction. 1994;9:1563–1570. - PubMed
-
- Balen A. H., Conway G. S., Kaltsas G., Techatrasak K., Manning P. J., West C., Jacobs H. S. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Human Reproduction. 1995;10:2107–2111. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous